6533b861fe1ef96bd12c5090

RESEARCH PRODUCT

Detection of a new 3-base pair insertion mutation in the protease gene of human immunodeficiency virus type 1 during highly active antiretroviral therapy (HAART).

Salvatrice MancusoTramuto FabioF BonuraNino RomanoFrancesco Vitale

subject

AdultSequence analysismedicine.medical_treatmentImmunologyMolecular Sequence DataGene Products polHIV InfectionsVirusHIV ProteaseVirologyAntiretroviral Therapy Highly ActivemedicineHumansInsertionCodonGeneBase PairingGeneticsProteasebiologyBase SequenceSequence Analysis DNAbiology.organism_classificationVirologyInfectious DiseasesLentivirusMutation (genetic algorithm)MutationHIV-1FemaleViral disease

description

To investigate a new insertion mutation in the protease (PR) gene of human immunodeficiency virus type 1 (HIV-1) in a patient extensively pretreated with antiretroviral drugs, genotypic analyses of plasma-derived viruses were performed by sequencing segments of 1302 nucleotides in the pol gene of HIV-1. Despite optimal compliance to highly active antiretroviral therapy (HAART) the patient showed poor virological success. Nucleotide sequences of retrospective available plasma samples exhibited a previously unknown 3-bp insertion mutation, corresponding to a leucine, between codons 31 and 32 of the PR gene. This kind of mutation appears to be very rare and it does not seem to be associated with any phenotypic resistance profile known so far. It should be noted that the insert mutation, once it appeared, did not revert to the wild-type variant, suggesting that it seems to correspond to a better fitness of the variant viruses.

10.1089/aid.2005.21.420https://pubmed.ncbi.nlm.nih.gov/15929706